Clinical Trial Update: A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 two-part trial (306A/306B) evaluated droxidopa for neurogenic orthostatic hypotension in Parkinson's disease; the study completed and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Orthostatic Hypotension
• Parkinson Disease

Drugs mentioned

• Northera (droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Orthostatic Hypotension, Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-05-20